Homocysteine and stroke

Current Opinion in Neurology

Volumn 14, Issue 1, 2001, Pages 95-102

  Hankey, Graeme J ^a,c   Eikelboom, John W ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b MCMASTER UNIVERSITY   (Canada)

^c ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZARIBINE; CARBAMAZEPINE; CYANOCOBALAMIN; ESTROGEN; FOLIC ACID; FOLIC ACID ANTAGONIST; HOMOCYSTEINE; METHOTREXATE; PHENYTOIN; PYRIDOXINE; THEOPHYLLINE;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTERY DISEASE; ATHEROGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; GENETIC DISORDER; HUMAN; HYPERHOMOCYSTEINEMIA; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; REVIEW; STROKE; THROMBOEMBOLISM; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VITAMIN SUPPLEMENTATION;

BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; HOMOCYSTEINE; HUMANS;

EID: 0035144894     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200102000-00015     Document Type: Review

References (63)

1. Treatment and secondary prevention of stroke: Evidence, costs, and effects on individuals and populations
2. Modeling of risk factors for ischemic stroke. The Willis Lecture
3. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis
4. Homocysteine and vascular disease
5. Blood levels of homocysteine and increased risks of cardiovascular disease: Causal or casual?
6. An alternative view of homocysteine
7. Plasma homocysteine as a cardiovascular risk factor: Causal, consequential, or of no consequence?
8. Homocysteine, hypertension and stroke
9. Homocysteine and atherosclerosis: Potential mechanisms and clinical implications
10. Homocysteine as a risk factor for atherosclerosis
11. The homocysteine question
12. Lowering blood homocysteine with folic acid based supplements meta-analysis of randomised trials
13. Assessment of homocysteine status
14. The metabolism of homocysteine: Pathways and regulation
15. Polymorphisms in the CβS gene associated with decreased risk of coronary artery disease and increased responsiveness to total homocysteine lowering by folic acid
16. Biochemistry and molecular genetics of cystathionine betasynthase deficiency
17. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methyltetrahydrofolate reductase genotypes
18. Genetic and nongenetic factors influencing plasma homocysteine levels in patients with ischaemic cerebrovascular disease and in healthy control subjects
19. Role of a common mutation in the homocysteine regulatory enzyme methylenetetrahydrofolate reductase in ischaemic stroke
20. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations
21. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: The Framingham Study
22. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly
23. The relation of plasma total homocysteine levels to prevalent cardiovascular disease in older patients with ischaemic stroke
24. Homocyst(e)ine and risk of cerebral infarction in a biracial population
25. Hyperhomocysteinaemia and hypofibrinolysis in young adults with ischaemic stroke
26. Hyperhomocysteinaemia. A risk factor for stroke in children
27. The risk of carotid atherosclerosis with hyperhomocysteinaemia and the C677T mutation of methylenetetrahydrofolate reductase
28. Plasma homocyst(e)ine concentration, but not MTHFR genotype, is associated with variation in carotid plaque area
29. Association between high homocyst(e)ine and ischaemic stroke due to large- and small-artery disease but not other etiological subtypes of ischaemic stroke
30. B vitamins, homocysteine, and neurocognitive function in the elderly
31. Homocysteine in cerebral macroangiopathy and microangiopathy
32. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: The Rotterdam Study
33. The A677V methylenetetrahydrofolate reductase gene polymorphism and carotid atherosclerosis
34. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis
35. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells
36. Effect of homocysteine on smooth muscle cell proliferation in both cell culture and artery perfusion culture models
37. Homocyst(e)ine induces calcium second messenger in vascular smooth muscle cells
38. The pathogenesis of atherosclerosis: A perspective for the 1990s
39. Homocysteine-induced endothelial cell injury in vivo: A model for the study of vascular injury
40. Acute hyperhomocyst(e)inaemia and endothelial dysfunction
41. Hyperhomocyst(e)inaemia is associated with impaired endothelium-dependent vasodilatation in humans
42. Hyperhomocysteinaemia after an oral methionine load acutely impairs endothelial function in healthy adults
43. Effects of methionine-induced hyperhomocysteinaemia on endothelium-dependent vasodilation and oxidative status in healthy adults
44. Role of oxidative stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans
45. Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects
46. Inhibition of endothelial cell thromboresistance by homocysteine
47. Homocysteine and oxidized low density lipoprotein enhances platelet adhesion to endothelial cells under flow conditions: Distinct mechanisms of thrombogenic modulation
48. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen
49. Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: Role for superoxide anions
50. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells
51. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinaemia: An effect reversible with vitamin C therapy
52. Impairment of endothelial functions by acute hyperhomocysteinaemia and reversal by antioxidant vitamins
53. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: Restoration by folic acid
54. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects
55. Influence of folic acid on postprandial endothelial dysfunction
56. Folic acid improves arterial endothelial function in adults with hyperhomocysteinaemia
57. What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 μmol/I
58. 6 on progression of subclinical atherosclerosis: A randomised, placebo-controlled trial
59. Endpoints for homocysteine-lowering trials
60. Can lowering homocysteine-levels reduce the incidence of stroke?
61. Major ongoing stroke trials
62. Major ongoing stroke trials
63. Homocyst(e)ine, diet, and cardiovascular diseases: A statement for healthcare professionals from the Nutrition Committee, American Heart Association